• Invest
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Product Suite
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    All Calculators
    Product Suite
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Market Movers
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Commodities
    Currency
    Futures & Options
    Derivatives
    Margin Trading
    Events
    Budget 2024
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2024
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Fund Expert
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

Sun Pharma’s Q1FY25 Results

Sun Pharma’s revenue increased 9% YoY
  • 02 Aug 2024
Read Full Article >
  • Sun Pharma reported a 5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter ended June (Q1FY25). On a year-on-year (YoY) basis, it witnessed a growth of 9%.
  • Its expenses for the quarter were up by 1% QoQ and 5% YoY.
  • The net profit grew 7% QoQ and 40% YoY.
  • The earnings per share (EPS) of Sun Pharma stood at 11.8 during Q1FY25.

Sun Pharma’s Financial Statements for Q1FY25:

(Rs crores) Q1FY24 Q4FY24 Q1FY25 QoQ (%) YoY (%)
Total income
12,145
12,589
13,185
5%
9%
Total expenses
9,341
9,672
9,762
1%
5%
Profit before tax
2,481
2,816
3,424
22%
38%
Tax
468
149
552
271%
18%
Profit after tax
2,023
2,655
2,836
7%
40%
Earnings per share
8.4
11.1
11.8

Financials:

  • Revenue: Revenue increased by 9% YoY to ₹13,185 crores, up from ₹12,145 crores in Q1FY24.
  • Net Profit: 40% YoY increase to ₹2,836 crores, from ₹2,023 crores in Q1FY24.
  • EBITDA: 8.3% YoY increase to ₹3,607 crores from ₹3,331.7 crores.
  • EBITDA Margin: Improved by 60 basis points to 28.5% from 27.9% in the same period last year.
  • Earnings per Share: The EPS for Q1FY25 stood at ₹11.8, compared to ₹8.4 in Q1FY24.
  • Indian Market Performance: Formulation sales in India increased by 16.4% to ₹4,144 crores (33.1% of total sales).
  • R&D Expenses: Increased to ₹794 crores, up from ₹680 crores in Q1FY24.

Management Commentary:

Dilip Shanghvi, Chairman and Managing Director of Sun Pharmaceutical Industries, said,

“Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe and the completion of the acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings and will help us serve patients better.”


Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -